Introduction
A number of recurrent chromosome translocations have been detected in lymphoid neoplasias, well characterized by molecular genetic studies, highlighting fundamental mechanisms of neoplastic transformation. 1 Some translocations showed an association with specific clinicopathological types: 2 with few exceptions, the t(14;18) is a diagnostic feature of follicular lymphoma; 3 the t(11;14)(q13;q32) indicates a follicle mantle origin; 4 the t(8;14)(q24;q32) identifies Burkitt's lymphoma and related disorders; 5, 6 the t(3;V)(q27;V) defines a genetically distinct subgroup of diffuse large cell lymphoma; 7 the t(2;5)(p23;q35) and the resulting overexpression of ALK protein is the hallmark of CD30
+ anaplastic large cell lymphoma. 8 Marginal zone B cell lymphoma (MZBCL) is a recently recognized entity of NHL usually running a relatively indolent clinical course, presenting three clinicopathological types, ie the extra-nodal form, the nodal and the splenic form. 9, 10 Although evidence was provided that distinct forms of MZBCL Correspondence: A Cuneo, Institute of Hematology, University of Ferrara, Via Savonarola, 9, 44100 Ferrara, Italy; Fax: +39-0532-212142 Received 3 April 2001; accepted 27 April 2001 share histologic and cytogenetic features, 11 more recently, some specific chromosome abnormalities have been described in discrete clinicopathological subtypes of this lymphoma. The t(11;18)(q21;q21) was found in an indolent form of extra-nodal MALT disease, 12 ,13 the t(1;14)(p21;q32) and the t(9;14)(p13;q32) were detected in sporadic cases of MZBCL [14] [15] [16] and a 7q31-32 deletion was found in splenic MZBCL. 17 We have found a previously undescribed chromosome translocation t(11,14)(p11;q32) in three cases of MZBCL. The results of clinicopathologic and molecular genetic studies are presented in this report.
Patients and methods
Since 1990 cytogenetic analysis has been part of the diagnostic work-up in the majority of patients with a lymphoid neoplasm referred to the Hematology Section, University of Ferrara. Karyotypes were analyzed in approximately 250 chronic (mature) lymphoid leukemias and 150 non-Hodgkin's lymphomas (NHL). The FAB criteria 18 and the REAL classifications 9 were used to recognize distinct disease entities, including chronic lymphocytic leukemia and related disorders, splenic lymphoma with villous lymphocytes, leukemic lymphomas and the various histologic forms of NHL. A novel t(11;14)(p11;q32) translocation was noted in two patients; in addition, the same translocation was recently found in a case studied in Brugge and Leuven, Belgium. These three patients form the basis of the present report.
Hematologic studies
Morphologic review of PB and BM smears in these patients was carried out. Immunophenotyping was part of the routine work-up at diagnosis and at disease evolution: methods in use at our institutions for cytofluorimetric analysis of immunologic profiles in chronic lymphoid disorders were previously published. 19 Pertinent clinical data were collected.
Cytogenetic studies
Conventional cytogenetic analysis was performed at diagnosis in all cases and on several occasions during follow-up in cases 1 and 2. PB samples were analyzed. A sample from jejunal resection was also analyzed in patient 2, according to methods previously described. 19, 20 Lymphoma cells were cultured for 24-72 h. The 72-h cultures were stimulated by mitogens 19 (phorbol myristate acetate and lypolysaccaride from E. coli).
A 72 h bone marrow culture stimulated with TPA was performed for patient 3.
Fluorescence in situ hybridization (FISH)
Probe selection:
The involvement of IgH in three cases with the t(11;14)(p11;q32) was analyzed by FISH using four probes: cos-C ␣1 for IgH-C ␣1 , 21 cosig 6 for IgH-C ␥3 , 22 cos3/64 for IgH (J H to C ␦ ) 23 and YAC Y6 for IGV H . 24 In addition, to better define the profile of chromosome lesions in patients 1 and 2, the following probes targeting chromosome regions frequently rearranged in lymphoid neoplasias were used: the C21 cosmid, recognizing DNA sequences between the Rb gene and the D13S25 marker at 13q14; 19 two lambda EMBL3 clones, spanning an area of approximately 40 kb in the mid portion of the ATM gene at 11q22.23; a 6q21 probe prepared by B Schlegelberger (Institute for Human Genetics, Kiel, Germany) as previously described, 25 commercially available centromeric probes recognizing chromosomes 3, 7 and 12 (Oncor, Gaithersburg, MD, USA). The following probes were also used which were made available in the context of the Biomed I programme, 'EU Concerted Action for Cytogenetic Diagnosis of Hematologic Malignancies' (project leader: A Hagemeijer, Centre for Human Genetic, KUL, Leuven, Belgium): a 17p13.3 cosmid recognizing p53 gene sequences, a cosmid probe located at 9p21 band, recognizing p16 sequences.
Hybridization conditions:
FISH was performed using cytogenetic fixed cell preparations, according to previously described protocols. 19, 26 Approximately 200 interphase cells with well-delineated signals were evaluated. Dual-color hybridization using the test probe and an irrelevant control probe was performed to rule out inefficient hybridization, as previously reported. 19 The probes were either biotin-, or digoxigenin-labelled and tested in five normal control samples: Ͻ1% cells showed three signals (false trisomy) and Ͻ3% cells showed one signal (false deletion) with each probe. The cut-off point for the recognition of trisomy and deletion was set at Ͼ3% cells with three signal and Ͼ10% cells with one signal, respectively.
Molecular genetic studies
A PB sample was obtained from patient 1 at diagnosis for molecular studies.
DNA, isolated from lymphocytes using proteinase K digestion, was phenol extracted and analyzed as previously reported. 27 Ten micrograms of DNA were digested with BamHI, EcoRI and HindIII, separated on agarose gel and Southern blotted. The configuration of BCL-1 locus was investigated using the following probes: a BCL-1/CCND1 cDNA (pPL8), 28 a major translocation cluster (MTC) BCL-1 'b', 29 a minor translocation cluster 1 (mTC1) p94PS. 30 The organization of the c-MYC and BCL-2 genes was analyzed respectively by hybridization with a c-MYC cDNA (Ryc 7.4) 31 and a 2.7 kb BCL-2 mbr region fragment. 32 The configuration of the BCL-6 locus was investigated using a Sac4.0 genomic fragment containing the 5Ј portion of BCL-6 gene and a Sac0.8 probe derived from the BCL-6 first intron. 33 A blood sample of patient 3 was studied by polymerase chain reaction (PCR) 34 for IGH, and BCL2-JH rearrangement and for BCL1 in RNA expression.
Leukemia

Results
Case histories and clinicopathologic data Case 1:
A 63-year-old-man was referred to our institution in 1992 with isolated lymphocytosis: the blood count showed WBC 12.3 × 10 9 /l with 65% lymphocytes with normal hemoglobin and platelet levels. Light microscopy examination of the PB smear showed a morphologically heterogeneous lymphoid population. The majority of cells were Ͼ14 m in size, with pleomorphism of nuclear shapes with fine chromatin structure and distinct nucleoli (Figure 1a) . Some rare lymphocytes with short villi were present along with larger lymphoid cells and rare prolymphocyte-like cells.
Immunophenotyping in the lymphocyte gate showed the following pattern of reactivity: pan-B antigens + (67% of the cells), CD22 bright+ (66%), FMC7
− . Surface immunoglobulins (sIg) were positive with bright staining pattern using anti-k/M/D serum (63% of the cells); the light chains, IgA and IgG tested negative. Fifteen percent morphologically abnormal lymphocytes were seen on a BM aspirate. No adenopathy was detected and a normal spleen size was documented by abdomen ultrasonography. The patient was followed at regular intervals in the outpatient department. In 1993 splenomegaly (3 cm below the left costal margin) without adenopathy was noted along with an increase of PB and BM lymphocytosis (WBC 35 × 10 9 /l with 50% abnormal lymphocytes in the BM). A bone biopsy documented numerous B lymphoid cells of intermediate size with an interstitial infiltration pattern; an intrasinusoidal pattern of growth was also noted by immunohistochemistry in some areas (Figure 1b) . Involvement of the gastric mucosa was excluded by endoscopic biospy. Several courses of chlorambucil or cyclophosphamide and a steroid drug were administered between 1994 and 1998, obtaining partial, short-term responses. Due to the development of progressive splenomegaly and anemia, multiagent chemotherapy using vincristine, cyclophosphamide and prednisone was initiated in 1999. The patient is currently alive with active disease, transfusion-dependent anemia and moderate thrombocytopenia.
Case 2:
A 65-year-old woman was referred to our institution in March 1997 with splenomegaly (8 cm below the left costal margin). A blood count showed Hb 11.3 g/dl, WBC 4.0 × 10 9 /l with a normal differential count; the platelets were within the normal range. Some atypical lymphocytes with monocytoid features were noted in a PB film and other lymphocytes displayed short cytoplasmic villi; no blast-like cells were seen. Immunophenotyping showed a moderate excess of B cells (20% in the lymphocyte gate) having the following reactivity: CD19
− . sIg /M/D were positive (10% of the cells); light chains IgA and IgG tested negative. The tartrate resistant acid-phosphatase stain was negative in the majority of lymphoid cells and the bone marrow was morphologically normal. Splenectomy was performed: histopathologic examination revealed numerous epithelioid granulomas and a nodular lymphoid infiltrate of the white pulp centered on polyclonal follicle centers, consistent with a diagnosis of splenic marginal zone B cell lymphoma (Figure 1d) . Biopsy of an abdominal lymph node did not show involvement by the neoplastic process at histologic examin- ation. The patient was treated by multiagent chemotherapy (cyclophosphamide, vincristine and prednisone for four courses) and attained complete remission. In September 1999, a jejunal lesion was documented and histologic examination of the resected intestinal segment documented an infiltrate by lymphoma cells with the features of marginal zone lymphocytes with a predominant large cell component. At that time PB and BM involvement by rare villous lymphocytes and by a majority of immunoblast-like cells was noted (see Figure 1c) . The blood count was Hb 11.3 g/dl, platelets 432 × 10 9 /l, WBC 33.7 × 10 9 /l with 65% lymphocytes and immunophenotyping confirming the proliferation of a CD19
− population, displaying the same immunologic profile as detected at diagnosis. Multiple adenopathies 1-2 cm in size were detected and the patient was treated by the CNOP regimen (cyclophosphamide, mitoxantrone, vincristine and prednisone). Only a partial response was recorded after two courses; the patient developed septic shock and died in December 1999.
Case 3:
A 81-year-old female was referred to the hematology unit at the S Jan Hospital in Brugge, Belgium, because of fatigue, night sweating, weight loss and left abdominal pain. Physical examination revealed splenomegaly (10 cm below the left costal margin), no hepatomegaly and no adenopathy. A blood count showed moderate anemia (Hb 11.3 g/dl), thrombocytopenia (platelets 92 × 10 9 /l) and a normal leukocyte count (WBC 6.4 × 10 9 /l) with 57% lymphocytes in the PB smear, 10% of which showed an atypical blast-like morphology.
A bone marrow aspirate showed normal erythropoiesis, granulocytopoiesis and megakarycytopoiesis. Twenty-two percent of lymphocytes were seen, some of which showed a somewhat dense nuclear chromatin with cytoplasmic projections.
Immunophenotyping on PB cells in the lymphocyte gate showed the following reactivity: CD19 The presence of each anomaly in interphase cells is indicated (% abnormal cells in parentheses); no indication means absence of the anomaly (probes for 6q21, 9p21, 11q22-23; 13q14, 17p13, centromeres of 3, 7, 12 were used). PB, peripheral blood; BM, bone marrow; ND, not done.
CD11c was weakly expressed (17%). Surface immunoglobulins K/M/A were positive. Lowered IgA and IgG levels and an IgM paraprotein were documented.
The patient was treated by chlorambucil for 2 months without response and splenectomy was performed. The spleen weighed 1140 g. At microscopic examination the white pulp appeared enlarged. Germinal centers were encircled by welldeveloped and enlarged mantle and marginal zones, which contained small lymphocytes mixed with larger blast cells with clear cytoplasm. In the red pulp and sinusoid similar lymphoid cells were also seen. Immunohistochemistry showed that the mantle and marginal zone was made of L26-positive lymphoid cells, which were negative for CD5, CD23, BCL2 and hairy cell leukemia marker, these features being consistent with a diagnosis of splenic lymphoma with villous lymphocytes (SLVL).
The patient is presently alive and well, 10 months after diagnosis and 8 months after splenectomy.
Cytogenetics, FISH and molecular genetics
The outcome of cytogenetic and FISH studies are summarized in Table 1 .
All three cases had the t(11;14)(p11;q32), shown in Figure  2 . In two patients (Nos 1 and 3) this novel translocation defined the stem line; several additional cytogenetic aberrations were seen, including a 17p deletion, present in both cases. In one patient a chromosome 7q deletion appeared to be the primary chromosome defect, the t(11;14)(p11;q32) translocation having been found in four out of 11 abnormal metaphase cells at disease progression.
The involvement of the IgH gene cluster in this t(11;14) was Leukemia demonstrated by dual-color FISH using locus-specific probes. In case 3 between one and three abnormal metaphases and 200 interphase cells were analyzed in each experiment. In cases 1 and 2 only interphase-FISH analysis could be performed. All abnormal metaphases analyzed in case 3 showed the same FISH pattern, namely, hybridization of cos-C ␣1 , cosIg6 and cos3/64 with the der(14) and hybridization of Y6 with the der(11). Separation of cos-C ␣1 and Y6 signals has been found in 105 out of 200 interphase cells analyzed in this case. Interphase-FISH analysis performed in cases 1 and 2 showed the same hybridization pattern as in case 3, namely separation of cos-C ␣1 /Y6 signals in approximately 60% and 65% of cells, respectively and cohybridization of cos-C ␣1 /cosIg6 and cos-C ␣1 /cos3/64 in more than 90% of cells. These findings indicate that the IgH breakpoint was located in the region flanked by cos3/64 and Y6, downstream of the IGV H sequences.
In patient 1, no rearrangement of BCL1, BCL2, BCL6, c-MYC were detected.
In patient 3 a monoclonal rearrangement of IgH was seen, BCL2-JH was negative, as was the the expression of BCL1 (Ͻ1%).
Discussion
The translocation t(11;14)(p11;q32) is probably rare. The Ferrara's series from which two of these cases were drawn consisted of approximately 400 lymphoid neoplasias karyotyped over a 10-year period, with a 6% global incidence of splenic marginal zone B cell lymphoma among approximately 150 histologically documented NHL. We found two cases in the literature with this translocation: one patient was described by Whang-Peng's group 35 in a report of 29 small lymphocytic lymphomas and another one with low grade histology was reported by Bloomfield et al. 36 Given the heterogeneity of classification systems it is possible that these cases may represent examples of MZBCL.
The diagnosis of splenic MZBCL was supported in our three cases bv cytoimmunologic and histologic findings.
In patients 1 and 3 a heterogeneous lymphoid population was present in the PB smear, including large blast-like cells with irregular monocytoid or cleft nuclei and distinct nucleoli. Whereas no change of morphology was noted in these patients throughout the course of the disease, the appearance of large blast-like cells was noted at relapse in patient 2 (see Figure 1c) . In all cases, few lymphocytes with short villi, grouped at one pole of the cytoplasm, were noted. It is noteworthy that many cases of splenic MZBCL may display a minority of villous lymphocytes in the PB smear 37, 38 and that the presence of a large-cell or blast-like cell component may alter the classical histologic picture in cases undergoing transformation from a classical MZBCL into a high-grade lymphoma. 39 An intrasinusoidal pattern of infiltration by lymphoma cells in the BM, lymph node or spleen, as noted in patients 1 and 3, was considered as a possible hallmark of splenic lymphoma. 40 Immunophenotypic profiles in our patients were consistent with previous descriptions of lymphoid neoplasias of marginal zone origin, which were shown to be mostly CD19
bright+ , FMC7 + and sIg bright+ . 41 Molecular cytogenetic investigations in our patients supported the splenic marginal-zone origin of the lymphoma cells. As expected, there was no cytogenetic evidence for the presence of any of the classical 14q32 translocations associated with lymphomas deriving from follicle center/post-germinal center cells or from the follicle mantle and these findings were confirmed by molecular genetic analyses in cases 1 and 3. Finally, the presence of +12, of 17p− and of 7q− represent relatively frequent findings in splenic MZBCL. 17, 42, 43 The t(11;14) was not the sole change in all cases (see Table  1 ). Interestingly, it was present in the stem line in patients 1 and 3, whereas it was observed in a side line in patient 2 (see Figure 2 ). We suggest that the t(11;14), occurring as a secondary change in this patient, appeared at the time of histologic switch into high-grade lymphoma.
Indeed, in all cases, a blast-like cell component was present in the PB smear when the t(11;14) was detected. In addition, this translocation was seen in every mitotic figure we were able to analyze from the high-grade jejunal lymphoma in patient 2. The appearance of specific chromosome translocations at histologic progression of a low-grade lymphoma into a high-grade lymphoma was well documented. 5, 44 The absence of rearrangements of the other principal B cell lymphoma-related genes (BCL1, BCL2, BCL6 c-MYC) and the paucity of cryptic chromosome deletions (11q−, 13q−, 6q−, 9p−), which are known to occur rather frequently in other lymphomas, 3, 45 suggest that transformation and/or tumor progression occurred through as yet unknown mechanisms, possibly involving a new gene at 11p11.
Splenic MZBCL notoriously shows frequent PB and BM dissemination. 37 The involvement of mucosa-associated lymphoid tissue in the gastro-intestinal tract, that was observed in patient 2, may be part of the natural history of the disorder. 11 Interestingly, a therapy-demanding disease was observed in patients 1 and 3 and histologic transformation into high-grade lymphoma occurred in patient 2. In addition, susceptibility to alkylating agents as well as to multiagent chemotherapy was unsatisfactory in our patients.
Thus, this novel translocation may be associated with a distinct clinicopathological subset of splenic MZBCL, characterized by the presence of a high-grade component in the spleen, BM and PB, and by a relatively aggressive clinical course.
